Pharmicell (005690) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.080x

Based on the latest financial reports, Pharmicell (005690) has a cash flow conversion efficiency ratio of 0.080x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.78 Billion ≈ $5.95 Million USD) by net assets (₩110.43 Billion ≈ $74.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pharmicell balance sheet independence to measure how much of total assets are equity-financed.

Pharmicell - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Pharmicell's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pharmicell (005690) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Pharmicell Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharmicell ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
African Gold Ltd AU:A1G	-0.063x
Tianjin Realty Development Group Co Ltd SHG:600322	-0.272x
Malteries Franco-Belges Société Anonyme PA:MALT	0.007x
Ashiana Housing Limited NSE:ASHIANA	0.120x
Colony Bankcorp Inc. NYSE:CBAN	0.143x
Dynasty Ceramic Public Company Limited BK:DCC	0.037x
V.S.T Tillers Tractors Limited NSE:VSTTILLERS	0.057x
Kalyani Steels Limited NSE:KSL	0.071x

Annual Cash Flow Conversion Efficiency for Pharmicell (2010–2024)

The table below shows the annual cash flow conversion efficiency of Pharmicell from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Pharmicell.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩86.44 Billion ≈ $58.58 Million	₩3.50 Billion ≈ $2.37 Million	0.040x	-72.46%
2023-12-31	₩80.40 Billion ≈ $54.48 Million	₩11.81 Billion ≈ $8.01 Million	0.147x	+42.35%
2022-12-31	₩76.66 Billion ≈ $51.95 Million	₩7.91 Billion ≈ $5.36 Million	0.103x	+226.26%
2021-12-31	₩63.87 Billion ≈ $43.28 Million	₩-5.22 Billion ≈ $-3.54 Million	-0.082x	-152.00%
2020-12-31	₩57.11 Billion ≈ $38.70 Million	₩8.98 Billion ≈ $6.08 Million	0.157x	+10828.39%
2019-12-31	₩51.52 Billion ≈ $34.91 Million	₩-75.50 Million ≈ $-51.16K	-0.001x	-102.04%
2018-12-31	₩47.49 Billion ≈ $32.18 Million	₩3.40 Billion ≈ $2.31 Million	0.072x	+300.00%
2017-12-31	₩55.99 Billion ≈ $37.95 Million	₩-2.01 Billion ≈ $-1.36 Million	-0.036x	-442.90%
2016-12-31	₩94.60 Billion ≈ $64.11 Million	₩988.97 Million ≈ $670.21K	0.010x	+132.06%
2013-12-31	₩82.42 Billion ≈ $55.86 Million	₩-2.69 Billion ≈ $-1.82 Million	-0.033x	+72.09%
2012-12-31	₩101.58 Billion ≈ $68.84 Million	₩-11.87 Billion ≈ $-8.04 Million	-0.117x	+40.15%
2011-12-31	₩82.82 Billion ≈ $56.13 Million	₩-16.17 Billion ≈ $-10.96 Million	-0.195x	+77.02%
2010-12-31	₩9.90 Billion ≈ $6.71 Million	₩-8.41 Billion ≈ $-5.70 Million	-0.850x	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$418.84 Million

₩618.04 Billion KRW

Market Cap Rank

#13032 Global

#356 in Korea

Share Price

₩10300.00

Change (1 day)

+1.68%

52-Week Range

₩8760.00 - ₩20250.00

All Time High

₩25150.00